[go: up one dir, main page]

GT200900319A - (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea - Google Patents

(oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea

Info

Publication number
GT200900319A
GT200900319A GT200900319A GT200900319A GT200900319A GT 200900319 A GT200900319 A GT 200900319A GT 200900319 A GT200900319 A GT 200900319A GT 200900319 A GT200900319 A GT 200900319A GT 200900319 A GT200900319 A GT 200900319A
Authority
GT
Guatemala
Prior art keywords
carboxamids
oxazolidinon
metil
thiophen
replaced
Prior art date
Application number
GT200900319A
Other languages
English (en)
Inventor
Allerheiligen Swen
Gnoth Mark Jean
Von Degenfeld Georges
Roehrig Susanne
Dittrich-Wengenroth Elke
Bauser Marcus
Heimbach Dirk
Heitmeier Stefan
Gerdes Christoph
Rester Ulrich
Saatmann Uwe
Tersteegen Adrian
Joachim Krueger
Holger Paulsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900319(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900319A publication Critical patent/GT200900319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

LA INVENCIÓN SE REFIERE A NUEVAS OXAZOLIDINONAS SUSTITUIDAS, A PROCEDIMIENTOS PARA SU PREPARACIÓN, A SU USO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES, DE FORMA PARTICULAR DE ENFERMEDADES TROMBÓTICAS.
GT200900319A 2007-06-20 2009-12-15 (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea GT200900319A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007028319A DE102007028319A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung

Publications (1)

Publication Number Publication Date
GT200900319A true GT200900319A (es) 2011-11-09

Family

ID=39731148

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900319A GT200900319A (es) 2007-06-20 2009-12-15 (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea

Country Status (42)

Country Link
US (2) US8383822B2 (es)
EP (1) EP2170877B1 (es)
JP (1) JP5537421B2 (es)
KR (1) KR101535312B1 (es)
CN (1) CN101821259B (es)
AR (2) AR066981A1 (es)
AU (1) AU2008266525B8 (es)
BR (1) BRPI0813736A2 (es)
CA (1) CA2692166C (es)
CL (1) CL2008001691A1 (es)
CO (1) CO6251281A2 (es)
CR (1) CR11168A (es)
CU (1) CU23820A3 (es)
CY (1) CY1113580T1 (es)
DE (1) DE102007028319A1 (es)
DK (1) DK2170877T5 (es)
DO (1) DOP2009000285A (es)
EC (1) ECSP099807A (es)
ES (1) ES2397799T3 (es)
GT (1) GT200900319A (es)
HN (1) HN2009003424A (es)
HR (1) HRP20130072T1 (es)
IL (1) IL202351A (es)
JO (1) JO2798B1 (es)
MA (1) MA31535B1 (es)
MX (1) MX2009013711A (es)
MY (1) MY150931A (es)
NZ (1) NZ581540A (es)
PA (1) PA8784301A1 (es)
PE (1) PE20090332A1 (es)
PL (1) PL2170877T3 (es)
PT (1) PT2170877E (es)
RS (1) RS52639B (es)
RU (1) RU2481345C2 (es)
SG (1) SG182220A1 (es)
SI (1) SI2170877T1 (es)
SV (1) SV2009003435A (es)
TN (1) TN2009000503A1 (es)
TW (1) TWI413642B (es)
UA (1) UA98793C2 (es)
UY (1) UY31133A1 (es)
WO (1) WO2008155032A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
WO2014183667A1 (zh) * 2013-05-17 2014-11-20 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103232446B (zh) * 2013-05-17 2015-09-23 天津药物研究院 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
ES2325045T3 (es) 1996-10-14 2009-08-24 Bayer Healthcare Ag Nuevos derivados de pirazol heterociclilmetil sustituidos y su uso en el tratamiento de enfermedades cardiovasculares.
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
US6259067B1 (en) 1998-10-16 2001-07-10 Medical Solutions, Inc. Temperature control system and method for heating and maintaining medical items at desired temperatures
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
EP1242417A1 (en) * 1999-12-21 2002-09-25 PHARMACIA & UPJOHN COMPANY Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TWI257389B (en) 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003006440A2 (en) * 2001-07-12 2003-01-23 Pharmacia & Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7265140B2 (en) * 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
HUE039135T2 (hu) 2003-11-12 2018-12-28 Daiichi Sankyo Co Ltd Eljárás tiazolszármazék elõállítására
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2005179272A (ja) 2003-12-19 2005-07-07 Yamanouchi Pharmaceut Co Ltd カルボキサミド誘導体のマロン酸塩結晶
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
BRPI0512273A (pt) 2004-06-18 2008-02-19 Millennium Pharm Inc inibidores do fator xa
US20060069260A1 (en) 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1864984A4 (en) 2005-03-31 2009-12-30 Mochida Pharm Co Ltd A TRICYCLIC SPIRO COMPOUND CONTAINING ANY ACYL GROUP CONTAINED IN THE NITROGEN IN THE RING
WO2007008142A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung

Also Published As

Publication number Publication date
MA31535B1 (fr) 2010-07-01
CY1113580T1 (el) 2016-06-22
CA2692166A1 (en) 2008-12-24
AU2008266525B8 (en) 2013-09-19
KR20100021615A (ko) 2010-02-25
UY31133A1 (es) 2009-01-30
US8846934B2 (en) 2014-09-30
SV2009003435A (es) 2010-08-23
UA98793C2 (ru) 2012-06-25
CU20090216A7 (es) 2011-10-14
RU2010101307A (ru) 2011-07-27
EP2170877A1 (de) 2010-04-07
PL2170877T3 (pl) 2013-03-29
TN2009000503A1 (en) 2011-03-31
AR066981A1 (es) 2009-09-23
EP2170877B1 (de) 2012-11-21
AU2008266525B2 (en) 2013-09-05
PE20090332A1 (es) 2009-04-09
US8383822B2 (en) 2013-02-26
HN2009003424A (es) 2012-01-05
DK2170877T3 (da) 2013-02-11
HRP20130072T1 (hr) 2013-02-28
PT2170877E (pt) 2013-01-28
TW200911797A (en) 2009-03-16
DE102007028319A1 (de) 2008-12-24
CL2008001691A1 (es) 2008-12-26
CR11168A (es) 2010-06-28
RS52639B (sr) 2013-06-28
PA8784301A1 (es) 2009-02-09
AR067057A1 (es) 2009-09-30
NZ581540A (en) 2012-01-12
AU2008266525A1 (en) 2008-12-24
CN101821259A (zh) 2010-09-01
JO2798B1 (en) 2014-03-15
SG182220A1 (en) 2012-07-30
IL202351A0 (en) 2010-06-30
CN101821259B (zh) 2013-10-30
TWI413642B (zh) 2013-11-01
US20140057951A1 (en) 2014-02-27
DOP2009000285A (es) 2010-01-31
BRPI0813736A2 (pt) 2014-12-30
WO2008155032A1 (de) 2008-12-24
JP5537421B2 (ja) 2014-07-02
SI2170877T1 (sl) 2013-03-29
US20100184740A1 (en) 2010-07-22
JP2010530383A (ja) 2010-09-09
CO6251281A2 (es) 2011-02-21
ECSP099807A (es) 2010-01-29
CA2692166C (en) 2015-01-27
KR101535312B1 (ko) 2015-07-09
MX2009013711A (es) 2010-02-01
RU2481345C2 (ru) 2013-05-10
DK2170877T5 (da) 2013-03-04
HK1147991A1 (en) 2011-08-26
ES2397799T3 (es) 2013-03-11
CU23820A3 (es) 2012-06-21
MY150931A (en) 2014-03-14
IL202351A (en) 2015-10-29

Similar Documents

Publication Publication Date Title
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
UY31765A (es) Dihidropirazolonas sustituidas y su uso
EP2220046A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP2220076A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP2220084A4 (en) INHIBITORS OF THE REPLICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
BRPI0914454A2 (pt) "composição para o tratamento do tecido epitelial"
MX2010003772A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il-1h-benzimidazol -4-carboxamida.